Malaysia
Search
Sign In
Product Highlight - TREZILENT
01 Dec 2020
•PIK3CA mutations are present in ~40% of HR+/HER2- aBC patients and indicate a poor prognosis2-9
•Trezilent specifically addresses PIK3CA mutations1,10
•Trezilent nearly doubled mPFS in patients with a PIK3CA mutation1,10
•Trezilent provides more than doubled response rate1,10
References:
1. Trezilent (alpelisib) Malaysia Package Leaflet. P1 RD 21 NOV 18 APPR 9 JUL 20. Novartis Pharma AG; May 2020.
2. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
3. Tolaney S, Toi M, Neven P, et al. Presented at: 2019 American Association for Cancer Research (AACR) Annual Meeting; March 29-April 3, 2019; Atlanta, GA.
4. Di Leo A, Johnston S, Seok Lee K, et al. Lancet Oncol. 2018;19(1):87-100.
5. Moynahan ME, Chen D, He W, et al. Br J Cancer. 2017;116(6):726-730.
6. Sobhani N, Roviello G, Corona SP, et al. The prognostic value of PI3K mutational status in breast cancer: a meta-analysis. J Cell Biochem. 2018;119(6):4287-4292.
7. Li YL, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat. 2006;96(1):91-95.
8. Lai YL, Mau, BL, Cheng WH, Chen HM, Chiu HH, Tzsen CY. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol. 2008;15(4):1064-1069.
9. Mosele F, Verret B, Jusque A, et al. Natural history and outcome of patients presenting a metastatic breast cancer with PIK3CA mutation. Abstract presented at: American Association for Cancer Research (AACR) Annual Meeting 2019; March 29-Apr 3, 2019; Atlanta, GA.
10. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929-1940.
•Trezilent specifically addresses PIK3CA mutations1,10
•Trezilent nearly doubled mPFS in patients with a PIK3CA mutation1,10
•Trezilent provides more than doubled response rate1,10
References:
1. Trezilent (alpelisib) Malaysia Package Leaflet. P1 RD 21 NOV 18 APPR 9 JUL 20. Novartis Pharma AG; May 2020.
2. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
3. Tolaney S, Toi M, Neven P, et al. Presented at: 2019 American Association for Cancer Research (AACR) Annual Meeting; March 29-April 3, 2019; Atlanta, GA.
4. Di Leo A, Johnston S, Seok Lee K, et al. Lancet Oncol. 2018;19(1):87-100.
5. Moynahan ME, Chen D, He W, et al. Br J Cancer. 2017;116(6):726-730.
6. Sobhani N, Roviello G, Corona SP, et al. The prognostic value of PI3K mutational status in breast cancer: a meta-analysis. J Cell Biochem. 2018;119(6):4287-4292.
7. Li YL, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat. 2006;96(1):91-95.
8. Lai YL, Mau, BL, Cheng WH, Chen HM, Chiu HH, Tzsen CY. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol. 2008;15(4):1064-1069.
9. Mosele F, Verret B, Jusque A, et al. Natural history and outcome of patients presenting a metastatic breast cancer with PIK3CA mutation. Abstract presented at: American Association for Cancer Research (AACR) Annual Meeting 2019; March 29-Apr 3, 2019; Atlanta, GA.
10. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929-1940.